Literature DB >> 16048260

Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious.

Caatje Y le Poole1, Angelique G A Welten, Marcel C Weijmer, Rob M Valentijn, Frans J van Ittersum, Piet M ter Wee.   

Abstract

BACKGROUND: The high Levels of glucose, glucose degradation products (GDPs), and lactate buffer present in standard peritoneal dialysis (PD) solutions contribute to peritoneal damage, malnutrition, and dyslipidemia. Therefore, we studied the feasibility of a PD regimen as low as possible in glucose and GDPs.
METHODS: In a prospective 30-week study, patients new to continuous ambulatory PD (CAPD) were randomized to either a standard PD regimen (SPD; 4 dwells glucose-/lactate-based) or a low glucose-GDP regimen (NEPP; 1 dwell amino acids, 1 dwell icodextrin, and two dwells bicarbonate/lactate-buffered glucose-based solution).
RESULTS: Results obtained during a 30-week study period for 63 new CAPD patients (30 NEPP, 33 SPD) were analyzed. Intraperitoneal glucose load was lower in the NEPP group (111 +/- 76 vs 159 +/- 40 g/day at 30 weeks, p < 0.001). Dialysis efficacy, ultrafiltration, weight, blood pressure, and laboratory results were similar in the groups, whereas, in the NEPP group, cancer antigen 125 in dialysate effluents decreased less but dialysate-to-plasma ratios were slightly higher.
CONCLUSION: Short-term treatment of new CAPD patients with a PD regimen low in glucose and GDPs is feasible. Dialysis efficacy, ultrafiltration, and metabolic consequences are similar to those during a standard glucose-lactate-based regimen, whereas peritoneal transport seems slightly higher and preservation of mesothelial cell mass better during NEPP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16048260

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  15 in total

Review 1.  Mechanisms and interventions in peritoneal fibrosis.

Authors:  Yasuhiko Tomino
Journal:  Clin Exp Nephrol       Date:  2011-09-21       Impact factor: 2.801

2.  "NEPP" peritoneal dialysis regimen has beneficial effects on plasma CEL and 3-DG, but not pentosidine, CML, and MGO.

Authors:  Caatje Y le Poole; Frans J van Ittersum; Rob M Valentijn; Tom Teerlink; Bengt Lindholm; Piet M Ter Wee; Casper G Schalkwijk
Journal:  Perit Dial Int       Date:  2011-05-31       Impact factor: 1.756

Review 3.  Increasing the use of biocompatible, glucose-free peritoneal dialysis solutions.

Authors:  Ahad Qayyum; Elizabeth Ley Oei; Klara Paudel; Stanley L Fan
Journal:  World J Nephrol       Date:  2015-02-06

Review 4.  Strategies for preventing peritoneal fibrosis in peritoneal dialysis patients: new insights based on peritoneal inflammation and angiogenesis.

Authors:  Zhen Zhang; Na Jiang; Zhaohui Ni
Journal:  Front Med       Date:  2017-08-08       Impact factor: 4.592

5.  Hyperbranched polyglycerol: a future alternative to polyglucose in peritoneal dialysis fluids?

Authors:  Bengt Rippe
Journal:  Perit Dial Int       Date:  2013 Jan-Feb       Impact factor: 1.756

6.  Higher plasma levels of von Willebrand factor and C-reactive protein during a peritoneal dialysis regimen with less glucose and glucose degradation products.

Authors:  Caatje Y le Poole; Casper G Schalkwijk; Tom Teerlink; Rob M Valentijn; Piet M Ter Wee; Frans J van Ittersum
Journal:  Perit Dial Int       Date:  2013 Mar-Apr       Impact factor: 1.756

7.  Solutions for peritoneal dialysis in children: recommendations by the European Pediatric Dialysis Working Group.

Authors:  Claus Peter Schmitt; Sevcan A Bakkaloglu; Günter Klaus; Cornelis Schröder; Michel Fischbach
Journal:  Pediatr Nephrol       Date:  2011-03-31       Impact factor: 3.714

8.  A peritoneal dialysis regimen low in glucose and glucose degradation products results in increased cancer antigen 125 and peritoneal activation.

Authors:  Caatje Y le Poole; Angelique G A Welten; Piet M ter Wee; Nanne J Paauw; Amina N Djorai; Rob M Valentijn; Robert H J Beelen; Jacob van den Born; Frans J van Ittersum
Journal:  Perit Dial Int       Date:  2011-11-01       Impact factor: 1.756

Review 9.  Pathogenesis and treatment of peritoneal membrane failure.

Authors:  Ramesh Saxena
Journal:  Pediatr Nephrol       Date:  2007-09-21       Impact factor: 3.714

Review 10.  Prevention of membrane damage in patient on peritoneal dialysis with new peritoneal dialysis solutions.

Authors:  Mufazzal Ahmad; Hemal Shah; Theodori Pliakogiannis; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2006-09-27       Impact factor: 2.266

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.